Adverum Biotechnologies, publicly traded is a clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, designed as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. On May 12, 2016, Adverum formed as a company after the closing on a transaction with Annapurna Therapeutics. The company announced its common stock will begin trading on Nasdaq under the symbol ADVM as of the open of market. Leone Paterson serves as Adverum’s president and chief executive officer, Aaron Osborne, MBBS, MRCOphth serves as chief medical officer, Thomas Leung as chief financial officer and Peter Soparkar as chief legal officer. In January 2020, the company announced the inauguration of its new corporate headquarters in Redwood City, California. The first building will be used as office space and laboratory space and the second building will enable expanded process development and manufacturing capabilities, pharmacodynamics laboratories, quality control laboratories, and warehouses. ADVM-022 is a gene therapy product developed for the treatment of neovascular age-related macular degeneration. The available therapies for treating wet AMD require life-long intravitreal injections every 4-12 weeks to maintain efficacy. A one-time IVT administration of ADVM-022 has the potential to treat wet AMD by providing durable expression of therapeutic levels of intraocular anti-VEGF protein and maintaining the vision of patients. ADVM-022 is designed to reduce the current treatment burden which often results in under-treatment and vision loss in patients with wet AMD receiving anti-VEGF therapy in clinical practice.